{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:53:17Z","timestamp":1787237597460,"version":"build-2736575974"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016387","name":"Grifols SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jns.2024.123314","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T10:20:47Z","timestamp":1732270847000},"page":"123314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Aging and infectious diseases in myasthenia gravis"],"prefix":"10.1016","volume":"468","author":[{"given":"Vera","family":"Bril","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Erik","family":"Gilhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123314_bb0005","volume":"2012","author":"Jayam Trouth","year":"2012","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.jns.2024.123314_bb0010","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48-49","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"issue":"11","key":"10.1016\/j.jns.2024.123314_bb0015","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0025","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch. Neurol."},{"issue":"10","key":"10.1016\/j.jns.2024.123314_bb0030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0035","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ana.21902","article-title":"Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus","volume":"67","author":"Cavalcante","year":"2010","journal-title":"Ann. Neurol."},{"issue":"6578","key":"10.1016\/j.jns.2024.123314_bb0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.jns.2024.123314_bb0045","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1212\/WNL.0b013e3181d7d884","article-title":"Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis","volume":"74","author":"Cavalcante","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.23869","article-title":"West nile virus infection and myasthenia gravis","volume":"49","author":"Leis","year":"2014","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0055","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/JTO.0000000000000390","article-title":"Detection of human polyomavirus 7 in human thymic epithelial tumors","volume":"10","author":"Rennspiess","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"issue":"5779","key":"10.1016\/j.jns.2024.123314_bb0065","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S0140-6736(00)94294-6","article-title":"Treatment of myasthenia gravis with physostigmine","volume":"223","author":"Walker","year":"1934","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2024.123314_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1203679","article-title":"The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan","volume":"14","author":"Herr","year":"2023","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0075","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207863","article-title":"Hospitalizations and mortality from myasthenia gravis: trends from 2 US National Datasets","volume":"102","author":"Habib","year":"2024","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0080","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","article-title":"Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany","volume":"33","author":"Mevius","year":"2023","journal-title":"Neuromuscul. Disord."},{"issue":"10","key":"10.1016\/j.jns.2024.123314_bb0085","first-page":"919","article-title":"Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study","volume":"95","author":"Vissing","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0090","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/0021-9681(58)90002-X","article-title":"Descriptive epidemiology of selected neurologic and myopathic disorders with particular reference to a survey in Rochester, Minnesota","volume":"8","author":"Kurland","year":"1958","journal-title":"J. Chronic Dis."},{"issue":"4978","key":"10.1016\/j.jns.2024.123314_bb0095","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/bmj.1.4978.1259","article-title":"Myasthenia gravis; a personal study of 60 cases","volume":"1","author":"Garland","year":"1956","journal-title":"Br. Med. J."},{"key":"10.1016\/j.jns.2024.123314_bb0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archneur.1960.00450040049006","article-title":"Myasthenia gravis in a southern community","volume":"3","author":"Alter","year":"1960","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0105","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1600-0404.1989.tb03793.x","article-title":"Epidemiological study of myasthenia gravis in Sardinia, Italy (1958-1986)","volume":"79","author":"Giagheddu","year":"1989","journal-title":"Acta Neurol. Scand."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0110","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0404.1968.tb07443.x","article-title":"The prevalence of some neurological diseases in Iceland","volume":"44","author":"Gudmundsson","year":"1968","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0022-510X(69)90090-2","article-title":"Epidemiology of myasthenia gravis in Finland","volume":"9","author":"Hokkanen","year":"1969","journal-title":"J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.jns.2024.123314_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274161","article-title":"Two-step nationwide epidemiological survey of myasthenia gravis in Japan 2018","volume":"17","author":"Yoshikawa","year":"2022","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0125","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1212\/WNL.59.1.92","article-title":"The occurrence of anti-titin antibodies and thymomas","volume":"59","author":"Somnier","year":"2002","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.jns.2024.123314_bb0130","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1212\/WNL.42.10.1888","article-title":"The epidemiology of myasthenia gravis in central and western Virginia","volume":"42","author":"Phillips","year":"1992","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0135","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0303-8467(00)00103-7","article-title":"Myasthenia gravis on the Dutch antilles: an epidemiological study","volume":"102","author":"Holtsema","year":"2000","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1600-0404.1984.tb00825.x","article-title":"Epidemiology of myasthenia gravis in Norway","volume":"70","author":"Storm-Mathisen","year":"1984","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2024.123314_bb0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000110138","article-title":"Neurological diseases in Karachi, Pakistan--elevated occurrence of subacute sclerosing panencephalitis","volume":"7","author":"Kondo","year":"1988","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0155","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0404.1992.tb05050.x","article-title":"Myasthenia gravis in Hong Kong Chinese. 1. Epidemiology and adult disease","volume":"86","author":"Yu","year":"1992","journal-title":"Acta Neurol. Scand."},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000116405","article-title":"Myasthenia gravis in the county of Viborg, Denmark","volume":"29","author":"S\u00f8rensen","year":"1989","journal-title":"Eur. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0404.1991.tb04654.x","article-title":"Comparative study on the prevalence of myasthenia gravis in the provinces of Bologna and Ferrara, Italy","volume":"83","author":"D\u2019Alessandro","year":"1991","journal-title":"Acta Neurol. Scand."},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0170","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1001\/archneur.1991.00530190081019","article-title":"Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey","volume":"48","author":"Somnier","year":"1991","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0175","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/jnnp.64.1.78","article-title":"Mortality and survival in myasthenia gravis: a Danish population based study","volume":"64","author":"Christensen","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0180","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000110923","article-title":"Epidemiology of myasthenia gravis in the province of Trento (northern Italy)","volume":"11","author":"Ferrari","year":"1992","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0185","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-0404.1999.tb00733.x","article-title":"Epidemiological and clinical characteristics of myasthenia gravis in Belgrade, Yugoslavia (1983-1992)","volume":"100","author":"Lavrni\u0107","year":"1999","journal-title":"Acta Neurol. Scand."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0190","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000109688","article-title":"Epidemiology of myasthenia gravis in northwestern Sardinia","volume":"16","author":"Aiello","year":"1997","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1023\/A:1007449221638","article-title":"Epidemiological study of myasthenia gravis in the province of Reggio Emilia, Italy","volume":"14","author":"Guidetti","year":"1998","journal-title":"Eur. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000026179","article-title":"Incidence and prevalence of myasthenia gravis in the county of the coast and Gorski kotar, Croatia, 1976 through 1996","volume":"17","author":"Zivadinov","year":"1998","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0205","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jnnp.65.4.492","article-title":"Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England","volume":"65","author":"Robertson","year":"1998","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0210","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000088674","article-title":"Epidemiological study of muscular disorders in Assiut, Egypt","volume":"25","author":"El-Tallawy","year":"2005","journal-title":"Neuroepidemiology"},{"issue":"12","key":"10.1016\/j.jns.2024.123314_bb0215","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/jnnp.74.12.1638","article-title":"A population based epidemiological study on myasthenia gravis in Estonia","volume":"74","author":"O\u00f6pik","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0220","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000065639","article-title":"Epidemiology of myasthenia gravis: a population-based study in Stockholm, Sweden","volume":"21","author":"Kalb","year":"2002","journal-title":"Neuroepidemiology"},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0225","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","article-title":"The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2007.05.002","article-title":"Epidemiology of autoimmune diseases in Denmark","volume":"29","author":"Eaton","year":"2007","journal-title":"J. Autoimmun."},{"issue":"11","key":"10.1016\/j.jns.2024.123314_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1819","article-title":"Epidemiology of myasthenia gravis in Sweden 2006-2016","volume":"10","author":"Westerberg","year":"2020","journal-title":"Brain Behav."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0240","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neurol.2024.02.392","article-title":"Epidemiology of myasthenia gravis in France: incidence, prevalence, and comorbidities based on national healthcare insurance claims data","volume":"180","author":"Keovilayhong","year":"2024","journal-title":"Rev. Neurol."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0245","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s10072-019-04146-1","article-title":"Hospital and healthcare insurance system record-based epidemiological study of myasthenia gravis in southern and northern China","volume":"41","author":"Fang","year":"2020","journal-title":"Neurol. Sci."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0250","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3349\/ymj.2016.57.2.419","article-title":"The epidemiology of myasthenia gravis in Korea","volume":"57","author":"Lee","year":"2016","journal-title":"Yonsei Med. J."},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0255","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3988\/jcn.2016.12.3.340","article-title":"Incidence and prevalence of myasthenia gravis in Korea: a population-based study using the National Health Insurance Claims Database","volume":"12","author":"Park","year":"2016","journal-title":"J. Clin. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000529583","article-title":"Incidence, prevalence, hospitalization rates, and treatment patterns in myasthenia gravis: a 10-year real-world data analysis of German claims data","volume":"57","author":"Wartmann","year":"2023","journal-title":"Neuroepidemiology"},{"issue":"3\u20134","key":"10.1016\/j.jns.2024.123314_bb0265","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000477733","article-title":"Incidence of autoimmune myasthenia gravis in a health maintenance Organization in Buenos Aires, Argentina","volume":"48","author":"Bettini","year":"2017","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0270","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40120-024-00619-4","article-title":"Epidemiology, patient characteristics, and treatment patterns of myasthenia gravis in Taiwan: a population-based study","volume":"13","author":"Tsai","year":"2024","journal-title":"Neurol. Ther."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0275","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16233","article-title":"The epidemiology and societal costs of myasthenia gravis in Norway: a non-interventional study using national registry data","volume":"31","author":"Engebretsen","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2024.123314_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1339167","article-title":"Epidemiology of myasthenia gravis in the United States","volume":"15","author":"Ye","year":"2024","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0285","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nrl.2020.06.011","article-title":"Epidemiology of myasthenia gravis in the province of Ourense (Galicia, Spain)","volume":"38","author":"Garcia Estevez","year":"2020","journal-title":"Neurologia"},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0290","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/mus.28077","article-title":"Epidemiology of seropositive myasthenia gravis in Sardinia: a population-based study in the district of Sassari","volume":"69","author":"Sechi","year":"2024","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0295","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neurol.2023.09.004","article-title":"Epidemiology of myasthenia gravis in France: a retrospective claims database study (STAMINA)","volume":"180","author":"Salort-Campana","year":"2024","journal-title":"Rev. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0300","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.28006","article-title":"Incidence and prevalence of myasthenia gravis in the United States: a claims-based analysis","volume":"69","author":"Rodrigues","year":"2024","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0305","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nmd.2015.10.009","article-title":"Epidemiology of myasthenia gravis in Ontario, Canada","volume":"26","author":"Breiner","year":"2016","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0310","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000279334","article-title":"The incidence of myasthenia gravis: a systematic literature review","volume":"34","author":"McGrogan","year":"2010","journal-title":"Neuroepidemiology"},{"issue":"17","key":"10.1016\/j.jns.2024.123314_bb0315","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","article-title":"Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada","volume":"76","author":"Pakzad","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.jns.2024.123314_bb0320","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cortes-Vicente","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123314_bb0325","unstructured":"World Health Organization, Global Health Estimates: Life Expectancy and Healthy Life Expectancy. Available at: https:\/\/www.who.int\/data\/gho\/data\/themes\/mortality-and-global-health-estimates\/ghe-life-expectancy-and-healthy-life-expectancy. Accessed 05 December 2024 World Health Organization, 2020."},{"key":"10.1016\/j.jns.2024.123314_bb0330","series-title":"Clinical Overview of MG","author":"Howard","year":"2015"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0335","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/jgs.12629","article-title":"Myasthenia gravis: a disease of the very old","volume":"62","author":"Aragon\u00e8s","year":"2014","journal-title":"J. Am. Geriatr. Soc."},{"issue":"10","key":"10.1016\/j.jns.2024.123314_bb0340","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0345","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mus.27369","article-title":"Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis","volume":"64","author":"Vijayan","year":"2021","journal-title":"Muscle Nerve"},{"issue":"1\u20132","key":"10.1016\/j.jns.2024.123314_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2012.10.028","article-title":"Myasthenia gravis in the elderly","volume":"325","author":"Hellmann","year":"2013","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.jns.2024.123314_bb0355","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/jnnp.2008.152637","article-title":"Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan","volume":"80","author":"Matsui","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2024.123314_bb0360","first-page":"127","article-title":"Myasthenia gravis: correlation of age with clinical course and anti-Achr antibody levels","volume":"12","author":"Kapinas","year":"2018","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0365","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40120-021-00312-w","article-title":"Low fluctuation of symptoms may delay diagnosis of myasthenia gravis: a case series","volume":"11","author":"Dragusin","year":"2022","journal-title":"Neurol. Ther."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0370","doi-asserted-by":"crossref","DOI":"10.1183\/20734735.0167-2021","article-title":"A late diagnosis of myasthenia gravis at the respiratory practice: back to basics","volume":"18","author":"Santy","year":"2022","journal-title":"Breathe"},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0375","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00281-020-00824-x","article-title":"The untwining of immunosenescence and aging","volume":"42","author":"Xu","year":"2020","journal-title":"Semin. Immunopathol."},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0380","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1159\/000478012","article-title":"Autoimmunity in the elderly: insights from basic science and clinics - a Mini-review","volume":"63","author":"Watad","year":"2017","journal-title":"Gerontology"},{"issue":"9","key":"10.1016\/j.jns.2024.123314_bb0385","doi-asserted-by":"crossref","first-page":"225","DOI":"10.31083\/j.fbl2809225","article-title":"Impact of Immunosenescence on viral infections with an emphasis on COVID-19","volume":"28","author":"Murdaca","year":"2023","journal-title":"Front. Biosci."},{"issue":"7913","key":"10.1016\/j.jns.2024.123314_bb0390","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","article-title":"Clonal dynamics of haematopoiesis across the human lifespan","volume":"606","author":"Mitchell","year":"2022","journal-title":"Nature"},{"issue":"50","key":"10.1016\/j.jns.2024.123314_bb0395","doi-asserted-by":"crossref","first-page":"20012","DOI":"10.1073\/pnas.1116110108","article-title":"Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age","volume":"108","author":"Pang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.jns.2024.123314_bb0400","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.humimm.2014.10.004","article-title":"Anti-pneumococcal deficits of monocyte-derived macrophages from the advanced-age, frail elderly and related impairments in PI3K-AKT signaling","volume":"75","author":"Verschoor","year":"2014","journal-title":"Hum. Immunol."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0405","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1474-9728.2004.00110.x","article-title":"Signal transduction and functional changes in neutrophils with aging","volume":"3","author":"Fulop","year":"2004","journal-title":"Aging Cell"},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0410","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1189\/jlb.70.6.881","article-title":"Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans","volume":"70","author":"Butcher","year":"2001","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"10.1016\/j.jns.2024.123314_bb0415","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1172\/JCI7558","article-title":"Analysis of the human thymic perivascular space during aging","volume":"104","author":"Flores","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-4943(00)00086-8","article-title":"Immunosenescence: a review","volume":"32","author":"Malaguarnera","year":"2001","journal-title":"Arch. Gerontol. Geriatr."},{"key":"10.1016\/j.jns.2024.123314_bb0425","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.mad.2013.12.003","article-title":"Nutrition, diet and immunosenescence","volume":"136-137","author":"Maijo","year":"2014","journal-title":"Mech. Ageing Dev."},{"issue":"9","key":"10.1016\/j.jns.2024.123314_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102893","article-title":"Immunosenescence in multiple sclerosis: the identification of new therapeutic targets","volume":"20","author":"Dema","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"25","key":"10.1016\/j.jns.2024.123314_bb0435","doi-asserted-by":"crossref","first-page":"15053","DOI":"10.1073\/pnas.2433717100","article-title":"CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly","volume":"100","author":"Haynes","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0440","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/eji.200526181","article-title":"Post-thymic in vivo proliferation of naive CD4+ T cells constrains the TCR repertoire in healthy human adults","volume":"35","author":"Kohler","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jns.2024.123314_bb0445","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1196\/annals.1354.018","article-title":"Naive T cells in the elderly: are they still there?","volume":"1067","author":"Pfister","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0450","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000501963","article-title":"Inflammation and the alteration of B-cell physiology in aging","volume":"66","author":"Hagen","year":"2020","journal-title":"Gerontology"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0455","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12979-020-00210-z","article-title":"Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination","volume":"17","author":"Frasca","year":"2020","journal-title":"Immun. Ageing"},{"issue":"10","key":"10.1016\/j.jns.2024.123314_bb0460","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.mad.2009.08.003","article-title":"A double-negative (IgD-CD27-) B cell population is increased in the peripheral blood of elderly people","volume":"130","author":"Colonna-Romano","year":"2009","journal-title":"Mech. Ageing Dev."},{"issue":"11","key":"10.1016\/j.jns.2024.123314_bb0465","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1432-2277.2009.00927.x","article-title":"The aging of the immune system","volume":"22","author":"Weiskopf","year":"2009","journal-title":"Transpl. Int."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0470","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0025-7125(16)30117-1","article-title":"Pneumonia in the elderly. Special diagnostic and therapeutic considerations","volume":"78","author":"Fein","year":"1994","journal-title":"Med. Clin. North Am."},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0475","doi-asserted-by":"crossref","DOI":"10.4110\/in.2019.19.e37","article-title":"Aging and the immune system: the impact of Immunosenescence on viral infection, immunity and vaccine immunogenicity","volume":"19","author":"Oh","year":"2019","journal-title":"Immune Netw."},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0480","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","volume":"180","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"10229","key":"10.1016\/j.jns.2024.123314_bb0485","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0490","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/M20-3905","article-title":"Patient trajectories among persons hospitalized for COVID-19","volume":"174","author":"Garibaldi","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jns.2024.123314_bb0495","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CIA.S25215","article-title":"Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence","volume":"7","author":"Lang","year":"2012","journal-title":"Clin. Interv. Aging"},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0500","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1073\/pnas.93.7.3043","article-title":"Chronic stress alters the immune response to influenza virus vaccine in older adults","volume":"93","author":"Kiecolt-Glaser","year":"1996","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0505","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.4161\/hv.28332","article-title":"Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine","volume":"10","author":"Park","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"10","key":"10.1016\/j.jns.2024.123314_bb0510","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.vaccine.2008.11.098","article-title":"Immunological responses to pneumococcal vaccine in frail older people","volume":"27","author":"Ridda","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0515","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1086\/520200","article-title":"Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity","volume":"29","author":"Romero-Steiner","year":"1999","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0520","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.beem.2010.08.014","article-title":"Sleep loss and inflammation","volume":"24","author":"Mullington","year":"2010","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jns.2024.123314_bb0525","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3389\/fimmu.2017.01385","article-title":"Aged gut microbiota contributes to Systemical Inflammaging after transfer to germ-free mice","volume":"8","author":"Fransen","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2024.123314_bb0530","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6757524","article-title":"Gastrointestinal tract disorders in older age","volume":"2019","author":"Dumic","year":"2019","journal-title":"Can. J. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0535","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10522-011-9353-4","article-title":"B cell immunosenescence: different features of naive and memory B cells in elderly","volume":"12","author":"Buffa","year":"2011","journal-title":"Biogerontology"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0540","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1038\/s41467-018-07825-3","article-title":"Impaired immune surveillance accelerates accumulation of senescent cells and aging","volume":"9","author":"Ovadya","year":"2018","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.jns.2024.123314_bb0545","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","article-title":"Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression","volume":"65","author":"Miller","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2024.123314_bb0550","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fnhum.2017.00316","article-title":"Inflammation: the common pathway of stress-related diseases","volume":"11","author":"Liu","year":"2017","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.jns.2024.123314_bb0555","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/289645","article-title":"Chronic inflammation in obesity and the metabolic syndrome","volume":"2010","author":"Monteiro","year":"2010","journal-title":"Mediat. Inflamm."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0560","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3945\/an.115.010207","article-title":"Impact of obesity and metabolic syndrome on immunity","volume":"7","author":"Andersen","year":"2016","journal-title":"Adv. Nutr."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0565","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/ene.14153","article-title":"Serious infections in patients with myasthenia gravis: population-based cohort study","volume":"27","author":"Kassardjian","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0570","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mus.27324","article-title":"COVID-19 in patients with myasthenia gravis: epidemiology and disease course","volume":"64","author":"Businaro","year":"2021","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-022-11389-0","article-title":"Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis","volume":"270","author":"Stascheit","year":"2023","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0580","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s00415-023-11733-y","article-title":"Myasthenia gravis, respiratory function, and respiratory tract disease","volume":"270","author":"Gilhus","year":"2023","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0585","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s13023-021-02090-y","article-title":"A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases","volume":"16","author":"Pisella","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0590","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mus.27743","article-title":"Impact of the COVID-19 pandemic on patients with myasthenia gravis: a survey of the Myasthenia Gravis Foundation of America MG patient registry","volume":"67","author":"De Leon","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2024.123314_bb0595","article-title":"COVID-19 outcomes in myasthenia gravis patients: analysis from electronic health Records in the United States","volume":"13","author":"Kim","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jns.2024.123314_bb0600","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2024.123314_bb0605","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211065406","article-title":"Advances and challenges in the treatment of myasthenia gravis","volume":"14","author":"Schneider-Gold","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"11","key":"10.1016\/j.jns.2024.123314_bb0610","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41582-020-0400-0","article-title":"Complement in neurological disorders and emerging complement-targeted therapeutics","volume":"16","author":"Dalakas","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0615","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0620","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11940-014-0283-8","article-title":"Treatment of MuSK-associated myasthenia gravis","volume":"16","author":"El-Salem","year":"2014","journal-title":"Curr. Treat. Options Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0625","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0630","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16180","article-title":"Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy","volume":"31","author":"Sacca","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0635","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0640","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200164","article-title":"Multiple sclerosis, disease-modifying therapies, and infections","volume":"10","author":"Langer-Gould","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jns.2024.123314_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving ocrelizumab or rituximab for treatment of MS and NMOSD","volume":"377","author":"Mears","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jns.2024.123314_bb0650","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/rheumatology\/kead328","article-title":"Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study","volume":"63","author":"Veeken","year":"2024","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0655","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of Thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.jns.2024.123314_bb0660","doi-asserted-by":"crossref","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","article-title":"High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"66","author":"McNamara","year":"2017","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.jns.2024.123314_bb0665","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1269325","article-title":"Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature","volume":"14","author":"Galli","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0670","first-page":"e22","article-title":"Detection of Neisseria meningitidis in a patient receiving ravulizumab by the FilmArray(R) meningitis\/encephalitis panel- a case report","volume":"82","author":"Navarro-Carrera","year":"2021","journal-title":"J. Inf. Secur."},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0675","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: the changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"12","key":"10.1016\/j.jns.2024.123314_bb0680","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci. Adv."},{"issue":"29","key":"10.1016\/j.jns.2024.123314_bb0685","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jns.2024.123314_bb0690","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5045\/kjh.2010.45.3.188","article-title":"The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma","volume":"45","author":"Yi","year":"2010","journal-title":"Korean J. Hematol."},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0695","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0700","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0705","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","article-title":"Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report","volume":"271","author":"Zhang","year":"2024","journal-title":"J. Neurol."},{"issue":"11","key":"10.1016\/j.jns.2024.123314_bb0710","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.jns.2024.123314_bb0715","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0720","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1186\/ar3453","article-title":"The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses","volume":"13","author":"Dixon","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0725","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mus.24697","article-title":"Mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark","volume":"53","author":"Hansen","year":"2016","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.jns.2024.123314_bb0730","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/jnnp.2005.072355","article-title":"Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001","volume":"77","author":"Owe","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0735","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/ene.12439","article-title":"Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study","volume":"21","author":"Andersen","year":"2014","journal-title":"Eur. J. Neurol."},{"issue":"17_supplement_1","key":"10.1016\/j.jns.2024.123314_bb0740","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000206555","article-title":"Analysis of serious infections and malignancy risk in myasthenia gravis: a US claims database study (P10-11.007)","volume":"102","author":"Podhorna","year":"2024","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0745","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.jval.2024.03.133","article-title":"CO44 exploring the impact of non-steroidal immunosuppressive drugs and steroids on the development of comorbidities in patients with myasthenia gravis in the National Veterans Affairs Health Network","volume":"27","author":"Qi","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0750","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12974-022-02448-4","article-title":"Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients","volume":"19","author":"Nelke","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.jns.2024.123314_bb0755","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s12883-023-03306-3","article-title":"Myasthenia gravis and independent risk factors for recurrent infection: a retrospective cohort study","volume":"23","author":"Chien","year":"2023","journal-title":"BMC Neurol."},{"issue":"6","key":"10.1016\/j.jns.2024.123314_bb0760","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","article-title":"Myasthenia gravis and infectious disease","volume":"265","author":"Gilhus","year":"2018","journal-title":"J. Neurol."},{"issue":"7","key":"10.1016\/j.jns.2024.123314_bb0765","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0770","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9834","article-title":"Outcomes of COVID-19 infection and vaccination among individuals with myasthenia gravis","volume":"6","author":"Alcantara","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jns.2024.123314_bb0775","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jns.2024.123314_bb0780","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/ITT.S261414","article-title":"Complement inhibition for the treatment of myasthenia gravis","volume":"9","author":"Mantegazza","year":"2020","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.jns.2024.123314_bb0785","unstructured":"US Food and Drug Administration, Alexion Briefing Information for the November 18, 2014. Available at: https:\/\/wayback.archive-it.org\/7993\/20170404151101\/https:\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/DrugSafetyandRiskManagementAdvisoryCommittee\/ucm423029.htm. Accessed 05 December 2024, Meeting of the Drug Safety and Risk Management Advisory Committee, 2014."},{"issue":"4","key":"10.1016\/j.jns.2024.123314_bb0790","first-page":"289","article-title":"The effectiveness of nucleoside analogues in chronic hepatitis B patients unresponsive to interferon therapy: our clinical trials for one year","volume":"10","author":"Kose","year":"2010","journal-title":"Hepat. Mon."},{"issue":"12","key":"10.1016\/j.jns.2024.123314_bb0795","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"Muppidi","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:58:33Z","timestamp":1736456313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24004507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":159,"alternative-id":["S0022510X24004507"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123314","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aging and infectious diseases in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123314","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"123314"}}